|
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
|
Jun 2015
|
Lancet Haematol
|
myelodysplastic syndromes (MDS)
|
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
|
Apr 2019
|
Haemotologica
|
myelodysplastic syndromes (MDS)
|
|
Use of eltrombopag for treatment of myelodysplastic syndromes
|
Mar 2017
|
Lancet Haematol
|
myelodysplastic syndromes (MDS)
|
|
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.
|
Jun 2013
|
Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
|
Jan 2017
|
J Hematol Oncol
|
aplastic anemia
|
|
Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review.
|
Apr 2017
|
Expert Rev Hematol
|
aplastic anemia
|
|
Update on the pharmacotherapy for myelodysplastic syndromes
|
Jul 2014
|
Expert Opin Pharmacother
|
myelodysplastic syndromes (MDS)
|
|
Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria
|
Dec 2016
|
Hematology Am Soc Hematol Educ Program
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Update in paroxysmal nocturnal hemoglobinuria
|
Jun 2012
|
Clin Adv Hematol Oncol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Unveiling the paradoxical nature of myelodysplastic syndromes (MDS): Why hypercellular marrow strongly favors accelerated apoptosis.
|
Mar 2013
|
Biochem Cell Biol
|
myelodysplastic syndromes (MDS)
|
